Incyte (INCY) said Thursday that Minjuvi, a treatment for relapsed or refractory follicular lymphoma, is being funded in Ontario through the province's Funding Accelerated for Specific Treatments, or FAST program.
The program enables eligible patients to gain access to the treatment sooner while formal reimbursement processes continue, the company said.
Price: 125.89, Change: -0.13, Percent Change: -0.10
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.